Mia T Minen1, Alexandra Boubour2, Harjasleen Walia3, William Barr4. 1. Department of Neurology, NYU Langone Medical Center, 240 East 38th Street 20th floor, New York, NY, 10016, USA. minenmd@gmail.com. 2. Barnard College, Columbia University, New York, NY, USA. 3. Department of Neurology, NYU Langone Medical Center, 240 East 38th Street 20th floor, New York, NY, 10016, USA. 4. Department of Neuropsychology, NYU Langone Medical Center, New York, NY, USA.
Abstract
PURPOSE OF REVIEW: Post-traumatic headache (PTH) is a secondary headache disorder following traumatic brain injury. We sought to examine the recent literature on PTH and associated cognitive, psychiatric, and sleep conditions to understand the latest findings about the associated conditions and available screening tools, and to understand the available treatment options for PTH. RECENT FINDINGS: Up to one third of PTH patients may have depression and about one quarter may have insomnia. Anxiety and cognitive issues are also common. While there are few studies examining abortive medications for PTH, recent studies of preventive medications examine the efficacy of topiramate, and topiramate may be better than other oral preventive medications. Other currently investigated treatments include nerve blocks, onabotulinum toxin A, transmagnetic stimulation, and behavioral therapy (biofeedback). Due to an expanded focus on and knowledge of concussion and PTH, comorbid psychiatric, cognitive, and sleep issues have become more widely acknowledged and studied. However, more high-quality studies must be conducted to examine the underlying pathophysiology of PTH and associated symptoms and to determine the most effective abortive and preventive treatment options.
PURPOSE OF REVIEW: Post-traumatic headache (PTH) is a secondary headache disorder following traumatic brain injury. We sought to examine the recent literature on PTH and associated cognitive, psychiatric, and sleep conditions to understand the latest findings about the associated conditions and available screening tools, and to understand the available treatment options for PTH. RECENT FINDINGS: Up to one third of PTH patients may have depression and about one quarter may have insomnia. Anxiety and cognitive issues are also common. While there are few studies examining abortive medications for PTH, recent studies of preventive medications examine the efficacy of topiramate, and topiramate may be better than other oral preventive medications. Other currently investigated treatments include nerve blocks, onabotulinum toxin A, transmagnetic stimulation, and behavioral therapy (biofeedback). Due to an expanded focus on and knowledge of concussion and PTH, comorbid psychiatric, cognitive, and sleep issues have become more widely acknowledged and studied. However, more high-quality studies must be conducted to examine the underlying pathophysiology of PTH and associated symptoms and to determine the most effective abortive and preventive treatment options.
Authors: Lindsay D Nelson; Ashley A LaRoche; Adam Y Pfaller; E Brooke Lerner; Thomas A Hammeke; Christopher Randolph; William B Barr; Kevin Guskiewicz; Michael A McCrea Journal: J Int Neuropsychol Soc Date: 2016-01 Impact factor: 2.892
Authors: Michael G Tramontana; Ronald L Cowan; David Zald; Jonathan W Prokop; Oscar Guillamondegui Journal: Brain Inj Date: 2014-07-02 Impact factor: 2.311
Authors: Laura S Moye; Madeline L Novack; Alycia F Tipton; Harish Krishnan; Subhash C Pandey; Amynah Aa Pradhan Journal: Cephalalgia Date: 2018-05-17 Impact factor: 6.292
Authors: Lisa M Betthauser; Jeri E Forster; Ann Bortz; Molly Penzenik; Theresa D Hernández; Nazanin Bahraini; Lisa A Brenner Journal: Contemp Clin Trials Commun Date: 2021-04-02